Hygeia Therapeutics develops topical therapies intended to provide localized treatment advantages over systemic options. Its lead asset is HYG-102, a topical synthetic estrogen; the company also plans development of HYG-440, a topical anti-androgen. Proceeds from the financing will advance proof-of-concept testing of HYG-102 for vaginal atrophy and fund preclinical proof-of-concept testing of HYG-102 for reversal of age-related skin thinning. The company intends to begin development work on HYG-440 with this financing. Dr. Yael Schwartz is CEO and co-founder and commented on the planned use of funds. The article lists the company location as Holden, MA.

Total raised

$1M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2010